LXEO Butterfly Strategy
LXEO (Lexeo Therapeutics, Inc. Common Stock), in the Healthcare sector, (Biotechnology industry), listed on NASDAQ.
Lexeo Therapeutics, Inc. operates as a clinical-stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of HCM caused by TNNI3 mutations. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York.
LXEO (Lexeo Therapeutics, Inc. Common Stock) trades in the Healthcare sector, specifically Biotechnology, with a market capitalization of approximately $452.3M, a beta of 1.53 versus the broader market, a 52-week range of 2.43-10.99, average daily share volume of 884K, a public-listing history dating back to 2023, approximately 75 full-time employees. These structural characteristics shape how LXEO stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 1.53 indicates LXEO has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a butterfly on LXEO?
A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration.
Current LXEO snapshot
As of May 15, 2026, spot at $5.09, ATM IV 17.00%, IV rank 0.00%, expected move 4.87%. The butterfly on LXEO below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 34-day expiry.
Why this butterfly structure on LXEO specifically: LXEO IV at 17.00% is on the cheap side of its 1-year range, which favors premium-buying structures like a LXEO butterfly, with a market-implied 1-standard-deviation move of approximately 4.87% (roughly $0.25 on the underlying). The 34-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated LXEO expiries trade a higher absolute premium for lower per-day decay. Position sizing on LXEO should anchor to the underlying notional of $5.09 per share and to the trader's directional view on LXEO stock.
LXEO butterfly setup
The LXEO butterfly below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With LXEO near $5.09, the first option leg uses a $4.84 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed LXEO chain at a 34-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 LXEO shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $4.84 | N/A |
| Sell 2 | Call | $5.09 | N/A |
| Buy 1 | Call | $5.34 | N/A |
LXEO butterfly risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit.
LXEO butterfly payoff curve
Modeled P&L at expiration across a range of underlying prices for the butterfly on LXEO. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use butterfly on LXEO
Butterflies on LXEO are pinning bets - traders use them when they expect LXEO to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
LXEO thesis for this butterfly
The market-implied 1-standard-deviation range for LXEO extends from approximately $4.84 on the downside to $5.34 on the upside. A LXEO long call butterfly is a pinning play: it pays maximum at the middle strike if LXEO settles there at expiration, with the wing legs capping both the cost and the maximum loss to the net debit. Current LXEO IV rank near 0.00% sits in the lower third of its 1-year distribution, where IV often re-expands toward the mean; this favors premium-buying structures and disadvantages premium-selling structures on LXEO at 17.00%. As a Healthcare name, LXEO options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to LXEO-specific events.
LXEO butterfly positions are structurally neutral / pin (limited-risk, limited-reward); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. LXEO positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move LXEO alongside the broader basket even when LXEO-specific fundamentals are unchanged. Always rebuild the position from current LXEO chain quotes before placing a trade.
Frequently asked questions
- What is a butterfly on LXEO?
- A butterfly on LXEO is the butterfly strategy applied to LXEO (stock). The strategy is structurally neutral / pin (limited-risk, limited-reward): A long call butterfly buys one lower-strike call, sells two ATM calls, and buys one higher-strike call, paying a small net debit for a defined-risk position that maxes out if the underlying pins the middle strike at expiration. With LXEO stock trading near $5.09, the strikes shown on this page are snapped to the nearest listed LXEO chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are LXEO butterfly max profit and max loss calculated?
- Max profit equals the wing width minus net debit times 100 (reached when the underlying pins the middle strike); max loss equals the net debit times 100. Two breakevens at lower-wing plus debit and upper-wing minus debit. For the LXEO butterfly priced from the end-of-day chain at a 30-day expiry (ATM IV 17.00%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a LXEO butterfly?
- The breakeven for the LXEO butterfly priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current LXEO market-implied 1-standard-deviation expected move is approximately 4.87%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a butterfly on LXEO?
- Butterflies on LXEO are pinning bets - traders use them when they expect LXEO to settle near a specific level at expiration (often the prior close, a round number, or the max-pain strike) and want defined-risk exposure to that outcome.
- How does current LXEO implied volatility affect this butterfly?
- LXEO ATM IV is at 17.00% with IV rank near 0.00%, which is on the low end of its 1-year range. Premium-buying structures (long call, long put, debit spreads) are relatively cheap in this regime; premium-selling structures collect less credit per unit risk.